Novel Therapeutic Rationale for Targeting HDAC1 and PIM2 in Multiple Myeloma

被引：0

作者：

Harada, Takeshi ^{[1
]}

Oda, Asuka ^{[1
]}

Ohguchi, Hiroto ^{[2
]}

Grondin, Yohann ^{[3
]}

Tenshin, Hirofumi ^{[4
]}

Hiasa, Masahiro ^{[4
]}

Teramachi, Jumpei ^{[5
]}

Oura, Masahiro ^{[1
]}

Sogabe, Kimiko ^{[1
]}

Fujii, Shiro ^{[1
]}

Nakamura, Shingen ^{[1
]}

Miki, Hirokazu ^{[6
]}

Kagawa, Kumiko ^{[1
]}

Ozaki, Shuji ^{[7
]}

Hideshima, Teru ^{[8
]}

Anderson, Kenneth C. ^{[8
]}

Abe, Masahiro ^{[1
]}

机构：

[1] Tokushima Univ, Inst Biomed Sci, Dept Hematol Endocrinol & Metab, Grad Sch, Tokushima, Japan

[2] Kumamoto Univ, Div Dis Epigenet, IRDA, Kumamoto, Japan

[3] Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, Mol & Integrat Physiol Sci Program, Boston, MA USA

[4] Tokushima Univ, Inst Biomed Sci, Dept Orthodont & Dentofacial Orthoped, Grad Sch, Tokushima, Japan

[5] Tokushima Univ, Inst Biomed Sci, Dept Tissue Regenerat, Grad Sch, Tokushima, Japan

[6] Tokushima Univ Hosp, Div Transfus Med & Cell Therapy, Tokushima, Japan

[7] Tokushima Prefectural Cent Hosp, Dept Hematol, Tokushima, Japan

[8] Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-127679

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3111

引用

页数：3

共 50 条

[1] Pinning down myeloma with Pim2 inhibitors!
Neri, Paola
Bahlis, Nizar J.
BLOOD, 2013, 122 (09) : 1534 - 1536
[2] Elucidating the Kinase-Independent Autoregulatory Loop of PIM2 in Multiple Myeloma
Schorr, Christopher
Petrusca, Daniela
Carlson, Louise
Hardwick, Joyce
Reinke, Julia Grace
Lee, Kelvin
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S197 - S198
[3] Novel inhibition of PIM2 kinase has significant anti-tumor efficacy in multiple myeloma
Nair, J. R.
Caserta, J.
Belko, K.
Howell, T.
Fetterly, G.
Baldino, C.
Lee, K. P.
LEUKEMIA, 2017, 31 (08) : 1715 - 1726
[4] The Critical Role of HDAC1-IRF4-Pim-2 Axis in Myeloma Cell Growth and Survival: Therapeutic Impacts of Targeting the HDAC1IRF4-Pim-2 Axis
Harada, Takeshi
Oda, Asuka
Grondin, Yohann
Teramachi, Jumpei
Bat-Erdene, Ariunzaya
Iwasa, Masami
Oura, Masahiro
Nakamura, Shingen
Kagawa, Kumiko
Okamoto, Yasunobu
Sogabe, Kimiko
Fujii, Shiro
Miki, Hirokazu
Ozaki, Shuji
Hideshima, Teru
Anderson, Kenneth C.
Abe, Masahiro
BLOOD, 2018, 132
[5] Novel inhibition of PIM2 kinase has significant anti-tumor efficacy in multiple myeloma
J R Nair
J Caserta
K Belko
T Howell
G Fetterly
C Baldino
K P Lee
Leukemia, 2017, 31 : 1715 - 1726
[6] Pim2 is important for regulating DNA damage response in multiple myeloma cells
Ramachandran, J.
Santo, L.
Siu, K. T.
Panaroni, C.
Raje, N.
BLOOD CANCER JOURNAL, 2016, 6 : e462 - e462
[7] Pim2 is important for regulating DNA damage response in multiple myeloma cells
J Ramachandran
L Santo
K T Siu
C Panaroni
N Raje
Blood Cancer Journal, 2016, 6 : e462 - e462
[8] Targeting the Pim kinases in multiple myeloma
N A Keane
M Reidy
A Natoni
M S Raab
M O'Dwyer
Blood Cancer Journal, 2015, 5 : e325 - e325
[9] Targeting the Pim kinases in multiple myeloma
Keane, N. A.
Reidy, M.
Natoni, A.
Raab, M. S.
O'Dwyer, M.
BLOOD CANCER JOURNAL, 2015, 5 : e325 - e325
[10] Targeting HDAC6 Is a Novel Approach to Augment the Therapeutic Benefit of Bromodomain Inhibition in Multiple Myeloma
Carew, Jennifer S.
Espitia, Claudia M.
Zhao, Weiguo
Kelly, Kevin R.
Nawrocki, Steffan T.
BLOOD, 2014, 124 (21)

← 1 2 3 4 5 →